PR
ProKidney Corp.
PROK · NASDAQ
$1.78 -5.08% (-$0.10)
1M +10.56%
Market Cap $263.0M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$2.26
27.3% upside
Current Price
$1.78
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PROK is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/S 321.51x
EV/EBITDA N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
0 /100
Weak Net margin 10,599.80%
Op. margin 21,664.50%
FCF margin 19,527.40%
Quality
0 /100
Poor ROA 34.82%
Asset turnover 0.00x
ROIC 68.08%
Debt
43 /100
Moderate Int. coverage -8,776.74x
Current ratio 8.36x
Net debt/EBITDA N/A
Stability
28 /100
Unstable EPS volatility 38.96%
Profitable years 0
Beta 1.75x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PROK
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Bruce Culleton
Employees
231
Headquarters
Winston-Salem
Upcoming events
09 NOV
Earnings
Upcoming earnings report